Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | F12 | P00748 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9684991 | 0.98 | CNR2 (0.51) | CNR2RAB9APLAUCYP2A6F12 | |
| SCHEMBL4404077 | 0.84 | CNR2 (0.64) | CNR2RAB9APLAUCYP2A6F12 | |
| SCHEMBL287165 | 0.82 | RAB9A (0.56) | CNR2RAB9APLAUCYP2A6F12 | |
| SCHEMBL5357601 | 0.82 | CNR2 (0.54) | CNR2RAB9APLAUCYP2A6F12 | |
| SCHEMBL29358323 | 0.81 | CNR2 (0.53) | CNR2RAB9APLAUCYP2A6F12 | |
| SCHEMBL22664584 | 0.81 | RAB9A (0.55) | CNR2RAB9APLAUCYP2A6F12 | |
| Hydrochloric Acid SCHEMBL3294760 | 0.81 | RAB9A (0.55) | CNR2RAB9APLAUCYP2A6F12 | |
| SCHEMBL970997 | 0.81 | CNR2 (0.53) | CNR2RAB9APLAUCYP2A6F12 | |
| SCHEMBL349832 | 0.81 | CNR2 (0.56) | CNR2RAB9APLAUCYP2A6F12 | |
| SCHEMBL28492272 | 0.81 | CNR2 (0.53) | CNR2RAB9APLAUCYP2A6F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110407808-B | Novel crystal form of (1S) -1-phenyl-3, 4-dihydro-1H-isoquinoline-2-carbonyl imidazole and preparation method thereof | 燃点(南京)生物医药科技有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-8598224-B2 | Method for treating cannabinoid receptor related diseases with cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20110086838-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7868038-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-01-11 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090075986-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20080187978-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-08-07 | — | — | US | disclosed |
| US-20080132506-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-06-05 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1773784-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| WO-2006014290-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050288286-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2005-12-29 | — | — | US | disclosed |
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | BAXTER ONCOLOGY GMBH | 2003-08-21 | — | — | US | disclosed |
| US-20020091124-A1 | 2-acyl indole derivatives and their use as antitumor agents | BECKERS THOMAS (DE) | 2002-07-11 | — | — | US | disclosed |
| US-5670511-A | Indolepiperidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-09-23 | — | — | US | disclosed |
| US-4001244-A | 1-ARYL-3,4-DIHYDRO-2(1H)-ISOQUINOLINE CARBONYL CHLORIDES | G. D. SEARLE & CO. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105230-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CNR2 597/4885RAB9A 4458/4885PLAU 822/4885 |
| US-20090075986-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CNR2 597/4885RAB9A 4458/4885PLAU 822/4885 |
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | CNR2 2183/4885RAB9A 3038/4885PLAU 1942/4885 |
| US-20050288286-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CNR2 597/4885RAB9A 4458/4885PLAU 822/4885 |
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | IDO1, IDO2, INMT | CNR2 1079/4885RAB9A 2603/4885PLAU 4658/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | CNR2 2183/4885RAB9A 3038/4885PLAU 1942/4885 |
| US-20020091124-A1 | 2-acyl indole derivatives and their use as antitumor agents | IDO1, IDO2, INMT | CNR2 1079/4885RAB9A 2603/4885PLAU 4658/4885 |
| US-20110086838-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPSR1 | CNR2 2/4885RAB9A 759/4885PLAU 4789/4885 |
| US-20080132506-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CNR2 597/4885RAB9A 4458/4885PLAU 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.